Literature DB >> 18765953

Enhanced ENA-78 and IL-8 expression in patients with malignant pancreatic diseases.

Vilma Oliveira Frick1, Claudia Rubie, Mathias Wagner, Stefan Graeber, Henner Grimm, Berit Kopp, Bettina M Rau, Martin K Schilling.   

Abstract

BACKGROUND/AIM: Pancreatic cancer is characterized by perineural invasion, early lymph node and liver metastases, and an extremely dismal prognosis. In the present study we aimed at investigating the expression profile of pro-inflammatory and angiogenic CXC chemokines as potential factors contributing to the aggressive biology of this gastrointestinal malignancy.
METHODS: Protein expression profiles of the CXC chemokines growth-related oncogene alpha (GRO-alpha/CXCL1), epithelial cell-derived neutrophil-activating peptide-78 (ENA-78/CXCL5), granulocyte chemoattractant protein-2 (GCP-2/CXCL6), neutrophil-activating protein-2 (NAP-2/CXCL7), and interleukin-8 (IL-8/CXCL8) were assessed by enzyme-linked immunosorbent assay in pancreatic carcinoma, cancer of the papilla of Vater, pancreatic cystadenoma, and chronic pancreatitis specimens.
RESULTS: IL-8 and ENA-78 protein expression was most pronounced in pancreatic carcinoma specimens, showing an 11-fold and 17-fold overexpression in comparison with non-affected neighbouring tissues, a 66-fold and 24-fold upregulation compared to pancreatic cystadenoma, and a 6-fold and 9-fold overexpression with respect to chronic pancreatitis, respectively (p < 0.05 between all groups). In addition, a close correlation between IL-8 and ENA-78 protein expression and advanced pancreatic carcinomas in relation to the T category was evident (p < 0.05).
CONCLUSION: Our results demonstrate that ELR+ CXC chemokines are differentially expressed in malignant and non-malignant human pancreatic specimens, suggesting a potential contribution of these chemokines to the pathogenesis of pancreatic carcinoma. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18765953     DOI: 10.1159/000151776

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  24 in total

Review 1.  Chemokines, chemokine receptors and the gastrointestinal system.

Authors:  Hiroshi Miyazaki; Kazuaki Takabe; W Andrew Yeudall
Journal:  World J Gastroenterol       Date:  2013-05-21       Impact factor: 5.742

2.  Bone marrow mast cell density correlates with serum levels of VEGF and CXC chemokines ENA-78 and GRO-α in multiple myeloma.

Authors:  C A Pappa; G Tsirakis; M Devetzoglou; M Zafeiri; R Vyzoukaki; A Androvitsanea; A Xekalou; K Sfiridaki; M G Alexandrakis
Journal:  Tumour Biol       Date:  2014-02-23

3.  CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes.

Authors:  Oksana Kowalczuk; Tomasz Burzykowski; Wieslawa Ewa Niklinska; Miroslaw Kozlowski; Lech Chyczewski; Jacek Niklinski
Journal:  Tumour Biol       Date:  2014-02-06

Review 4.  Kras and Tumor Immunity: Friend or Foe?

Authors:  Jane Cullis; Shipra Das; Dafna Bar-Sagi
Journal:  Cold Spring Harb Perspect Med       Date:  2018-09-04       Impact factor: 6.915

5.  Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers.

Authors:  Shalini Makawita; Chris Smith; Ihor Batruch; Yingye Zheng; Felix Rückert; Robert Grützmann; Christian Pilarsky; Steven Gallinger; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2011-06-07       Impact factor: 5.911

6.  CXCL5 regulation of proliferation and migration in human non-small cell lung cancer cells.

Authors:  Lin Wang; Lin Shi; Jie Gu; Cheng Zhan; Junjie Xi; Jianyong Ding; Di Ge
Journal:  J Physiol Biochem       Date:  2018-03-10       Impact factor: 4.158

7.  CXCR2 macromolecular complex in pancreatic cancer: a potential therapeutic target in tumor growth.

Authors:  Shuo Wang; Yanning Wu; Yuning Hou; Xiaoqing Guan; Marcello P Castelvetere; Jacob J Oblak; Sanjeev Banerjee; Theresa M Filtz; Fazlul H Sarkar; Xuequn Chen; Bhanu P Jena; Chunying Li
Journal:  Transl Oncol       Date:  2013-04-01       Impact factor: 4.243

Review 8.  CXCR2: a target for pancreatic cancer treatment?

Authors:  Kathleen M Hertzer; Graham W Donald; O Joe Hines
Journal:  Expert Opin Ther Targets       Date:  2013-02-21       Impact factor: 6.902

9.  Semi mature blood dendritic cells exist in patients with ductal pancreatic adenocarcinoma owing to inflammatory factors released from the tumor.

Authors:  Vegard Tjomsland; Anna Spångeus; Per Sandström; Kurt Borch; Davorka Messmer; Marie Larsson
Journal:  PLoS One       Date:  2010-10-15       Impact factor: 3.240

10.  A crucial role for TNF-alpha in mediating neutrophil influx induced by endogenously generated or exogenous chemokines, KC/CXCL1 and LIX/CXCL5.

Authors:  S M Vieira; H P Lemos; R Grespan; M H Napimoga; D Dal-Secco; A Freitas; T M Cunha; W A Verri; D A Souza-Junior; M C Jamur; K S Fernandes; C Oliver; J S Silva; M M Teixeira; F Q Cunha
Journal:  Br J Pharmacol       Date:  2009-08-20       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.